Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Cell-Penetrating Peptides to Enhance Delivery of Oligonucleotide-Based Therapeutics.

Journal article

McClorey G. and Banerjee S., (2018), Biomedicines, 6


Conference paper

Betts CA. et al, (2018), HEART, 104, A4 - A4

Splice-Switching Therapy for Spinal Muscular Atrophy.

Journal article

Meijboom KE. et al, (2017), Genes (Basel), 8

Antisense pre-treatment increases gene therapy efficacy in dystrophic muscles.

Journal article

Peccate C. et al, (2016), Hum Mol Genet, 25, 3555 - 3563

Multi-level omics analysis in a murine model of dystrophin loss and therapeutic restoration.

Journal article

Roberts TC. et al, (2015), Hum Mol Genet, 24, 6756 - 6768

An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies.

Journal article

McClorey G. and Wood MJ., (2015), Curr Opin Pharmacol, 24, 52 - 58

The physiological consequences of different levels of dystrophin following antisense based exon-skipping in the mdx mouse

Conference paper

Muses S. et al, (2015), NEUROMUSCULAR DISORDERS, 25, S312 - S313

Peptide nanoparticle delivery of charge-neutral splice-switching morpholino oligonucleotides.

Journal article

Järver P. et al, (2015), Nucleic Acid Ther, 25, 65 - 77

Load More